EXKIVITY (mobocertinib) capsules
EXKIVITY is used to treat adult patients with a kind of lung cancer called non-small cell lung cancer (NSCLC). Brand Name: EXKIVITY (mobocertinib) capsules, for oral use Initial U.S. Approval: 2021
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
Call / WhatsApp Number
+91 9289711088 (Ms. Laxmi Singh)
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
EXKIVITY (mobocertinib) capsules
Mobocertinib succinate is approved to treat: Non-small cell lung cancer (NSCLC). Mobocertinib succinate is also being studied in the treatment of other conditions.
A drug used to treat adults with non-small cell lung cancer that has spread and has certain mutations (changes) in the EGFR gene. It is used in patients whose cancer got worse during or after platinum chemotherapy. It is also being studied in the treatment of other conditions. Exkivity blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called mobocertinib succinate.
Mobocertinib is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Drug (Brand / Generic): EXKIVITY / mobocertinib
Current Indications: Non-small cell lung cancer (NSCLC)
Marketed by:: Takeda Pharmaceuticals America, Inc
Approval Date: 2021
Dosage forms and strengths of EXKIVITY (mobocertinib).
Capsules: 40 mg
Find Reference Updates
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
Gonzalvez F, et al., Cancer discovery, Jul 2021
FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
FDA press release, Sep 2021
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ EXKIVITY (mobocertinib) capsules ”. Confirmation of the order for EXKIVITY (mobocertinib) capsules will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – EXKIVITY
For personal use, get access to an imported medicines (unapproved drug in India) for lung cancer. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Karnataka, Bangalore, Bhopal, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Dispur, Guwahati, Dehradun, Lucknow, Surat, Nagpur, New Delhi, Pondichery, Pune, Itanagar, Bathinda, Thirunananthapuram, Visakhapatnam, Chandigarh, Faridabad, Gurgaon, Agartala, Shillong, Goa, Wardha, Shimla, Dharamshala, Aizawl, Noida, Ghaziabad, Punjab.
EXKIVITY Sourcing & Delivery
Alleviare India specializes in sourcing and supplying EXKIVITY, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of EXKIVITY in India.
How much does EXKIVITY cost in the India?
Kindly reach out to us for EXKIVITY (mobocertinib) capsules price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import EXKIVITY to India?
To import mobocertinib EXKIVITY, patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
Valid prescription from a qualified doctor.
Patients’ diagnostic reports.
Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
Valid prescription from the doctor.
Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is EXKIVITY available in India?
EXKIVITY mobocertinib is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of EXKIVITY (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for EXKIVITY availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is mobocertinib available in India?
On September 15, 2021, the Food and Drug Administration granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand EXKIVITY (mobocertinib) capsules. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to EXKIVITY (mobocertinib) capsules , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
